848089-63-4

Upstream product

• 20725-25-1 1,3-bis(4-chlorophenyl)prop-2-en-1-one 
• 105-53-3 diethyl malonate 
• 19672-59-4 (E)-1,3-di(4-chlorophenyl)-2-propen-1-one 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 1221962-79-3 2-[1,3-bis(4-chlorophenyl)-3-oxopropyl]malonic acid 

Relevant academic research and scientific papers

Exploring bis-(amino)cyclopropenylidene as a non-covalent Br?nsted base catalyst in conjugate addition reactions

Bis-(amino)cyclopropenylidene has been utilised as a non-covalent Br?nsted base catalyst in the 1,6-conjugate addition of carbon nucleophiles to p-QMs. This protocol makes it possible to access unsymmetrical diaryl- and triarylmethanes in good to excellen

2-(3-oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: Development and prodrug concept

The protein kinase C-related kinase 2 (PRK2)-interacting fragment (PIF) pocket of phosphoinositide-dependent kinase-1 (PDK1) was proposed as a novel target site for allosteric modulators. In the present work, we describe the design, synthesis, and structure-activity relationship of a series of 2-(3-oxo-1,3-diphenylpropyl)malonic acids as potent allosteric activators binding to the PIF pocket. Some congeners displayed AC50 values for PDK1 activation in the submicromolar range. The potency of the best compounds to stabilize PDK1 in a thermal stability shift assay was in the same order of magnitude as that of the PIF pocket binding peptide PIFtide, suggesting comparable binding affinities to the PIF pocket. The crystal structure of PDK1 in complex with compound 4h revealed that additional ionic interactions are mainly responsible for the increased potency compared to the monocarboxylate analogues. Notably, several compounds displayed high selectivity for PDK1. Employing a prodrug strategy, we were able to corroborate the novel mechanism of action in cells.

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

1H and 13C NMR studies of some 1, 1 -bis(carbethoxy)-2-aryl-4-phenyl/(4- chlorophenyl)-4-oxobutane and their derivatives

The 1H and 13C NMR spectral features of l, l-bis(carbethoxy)-2-aryl-4- phenyl/(4-chlorophenyl)-4-oxobutane la-j and their carbonyl derivatives 2a-e are discussed in the light of their diastereotopic characteristics and preferred conformational structures

Synthesis and spectral characterization of diethyl 2-[aryl(4-aryl-1,2,3- selenadiazol-5-yl)methyl]malonate

Synthesis and characterization of several diethyl 2-[aryl(4-aryl-1,2,3- selenadiazol-5-yl)methyl]malonates are reported.